On the other hand, the impact of CAR T‐cell therapies on cancer patients that carry CHIP seems to be more heterogenous and probably disease dependent, with studies suggesting no impact [66], increased rates of complete response and cytokine release syndrome (CRS) severity in patients younger than age 60 years [67], or increased risk of immune effector cell‐associated neurotoxicity syndrome (ICANS), CRS severity, and higher cumulative incidence of therapy‐related myeloid neoplasms after CAR T‐cell therapy [68]. Here, STUB1 is linked to congenital rubella syndrome.